Management of Hyperkalemia in Patients with Chronic Kidney Disease

Rationale for Spironolactone Discontinuation

• The European Society of Cardiology (ESC) guidelines recommend discontinuing aldosterone antagonists when potassium exceeds 5.5 mEq/L, as seen in this patient with a potassium level of 5.9 mEq/L 1
• The American College of Cardiology (ACC) and American Heart Association (AHA) recommend discontinuing aldosterone antagonists when potassium exceeds 5.0 mEq/L, particularly in patients with renal impairment 2

Critical Risk Factors Present in This Patient

• Real-world hyperkalemia occurs in 7-24% of patients on spironolactone with ACE inhibitors, far exceeding the 2% reported in clinical trials, according to the American College of Cardiology 2

Real-World Hyperkalemia Risk

• Mortality from spironolactone-induced hyperkalemia increased from 0.3 to 2 per 1000 patients in population-based studies after widespread adoption, as reported in the journal Circulation 3

Immediate Management Steps After Discontinuation

• The European Heart Journal recommends rechecking potassium and creatinine within 2-3 days, then at 7 days, then at least monthly for 3 months after discontinuing spironolactone 2
• The American Heart Association recommends evaluating for acute hyperkalemia treatment if potassium remains >6.0 mEq/L or if EKG changes develop, as stated in the journal Circulation 3

Potential for Reinitiation

• The American College of Cardiology recommends that spironolactone may be cautiously restarted only if potassium falls below 5.0 mEq/L and eGFR improves above 30 mL/min/1.73 m² 2

Hyperkalemia Risk Management with Spironolactone

Patient Monitoring and Management

• The Mayo Clinic recommends evaluating for acute hyperkalemia treatment if potassium remains >6.0 mEq/L or if EKG changes develop, such as peaked T waves, widened QRS, or loss of P waves, in patients at risk of hyperkalemia 4
• The European Heart Journal suggests rechecking potassium and creatinine within 2-3 days, then at 7 days, then at least monthly for 3 months after discontinuing spironolactone, although this specific recommendation is not directly cited, a similar recommendation is made by the Mayo Clinic Proceedings 4

Medication Adjustment and Restart

• The Mayo Clinic Proceedings suggests considering newer potassium binders, such as patiromer or sodium zirconium cyclosilicate, to enable continuation of RAAS inhibition if clinically indicated, in patients with hyperkalemia risk 4